0VQ0.F PURETECH HLTH ADRS 10

Healthcare Biotechnology Frankfurt Exchange
14.20 EUR
Close of Nov 11, 2026
11.30 16.90
Market cap
EUR 346M
P/E
-
P/B
0.98x
ROE
-35.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 0VQ0.F undervalued?

Graham number

The Graham number of PURETECH HLTH ADRS 10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PURETECH HLTH ADRS 10 fundamental analysis

No fundamental analysis for PURETECH HLTH ADRS 10 yet.

PURETECH HLTH ADRS 10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PURETECH HLTH ADRS 10

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnano…

Full company profile